PharmaShots | Incisive News in 3 Shots

Subscribe Now

HER2-

Celltrion and MSD Report Results of First-Line Triplet Regimen P-I/II PANTHERA trial in Patients with HER2-Positive Advanced Gastric Cancer

Celltrion and MSD Report Results of First-Line Triplet Regimen P-I/II PANTHERA trial in Patients with HER2-Positive Advanced Gastr...

May 27, 2020

Novartis' Piqray (alpelisib) + Fulvestrant Receive FDA's Approval for Patients with a PIK3CA Mutation in HR+/HER2- Advanced/Metastatic Breast Cancer

Novartis' Piqray (alpelisib) + Fulvestrant Receive FDA's Approval for Patients with a PIK3CA Mutation in HR+/HER2- Advanced/Metast...

May 27, 2019

Novartis' Kisqali + Aromatase Inhibitor Receive FDA's Breakthrough Therapy Designation for HR+/HER2- Advanced Breast Cancer

Novartis' Kisqali + Aromatase Inhibitor Receive FDA's Breakthrough Therapy Designation for HR+/HER2- Advanced Breast Cancer

January 3, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us